Dezhan Healthcare Past Earnings Performance
Past criteria checks 2/6
Dezhan Healthcare's earnings have been declining at an average annual rate of -63.7%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been declining at an average rate of 38.9% per year. Dezhan Healthcare's return on equity is 0.6%, and it has net margins of 13.9%.
Key information
-63.7%
Earnings growth rate
-63.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -38.9% |
| Return on equity | 0.6% |
| Net Margin | 13.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Dezhan Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 464 | 65 | 261 | 50 |
| 31 Dec 23 | 498 | 83 | 268 | 51 |
| 30 Sep 23 | 514 | -75 | 285 | 56 |
| 30 Jun 23 | 488 | -120 | 282 | 55 |
| 31 Mar 23 | 513 | -75 | 298 | 53 |
| 01 Jan 23 | 571 | -47 | 304 | 51 |
| 30 Sep 22 | 638 | -116 | 334 | 49 |
| 30 Jun 22 | 647 | -95 | 344 | 55 |
| 31 Mar 22 | 716 | -91 | 351 | 59 |
| 01 Jan 22 | 734 | -58 | 344 | 67 |
| 30 Sep 21 | 637 | 170 | 288 | 73 |
| 30 Jun 21 | 640 | 205 | 209 | 68 |
| 31 Mar 21 | 704 | 257 | 208 | 59 |
| 31 Dec 20 | 963 | 285 | 361 | 56 |
| 30 Sep 20 | 1,209 | 238 | 561 | 64 |
| 30 Jun 20 | 1,568 | 277 | 792 | 91 |
| 31 Mar 20 | 1,764 | 308 | 921 | 122 |
| 31 Dec 19 | 1,775 | 337 | 961 | 119 |
| 30 Sep 19 | 2,048 | 539 | 1,070 | 113 |
| 30 Jun 19 | 2,552 | 729 | 1,400 | 82 |
| 31 Mar 19 | 2,984 | 873 | 1,649 | 76 |
| 31 Dec 18 | 3,291 | 931 | 1,867 | 87 |
| 30 Sep 18 | 3,505 | 894 | 2,063 | 96 |
| 30 Jun 18 | 3,086 | 814 | 1,736 | 109 |
| 31 Mar 18 | 2,658 | 812 | 1,355 | 77 |
| 31 Dec 17 | 2,220 | 797 | 972 | 55 |
| 30 Sep 17 | 1,750 | 775 | 575 | 23 |
| 30 Jun 17 | 1,585 | 765 | 432 | 0 |
| 31 Mar 17 | 1,485 | 694 | 411 | 0 |
| 31 Dec 16 | 1,443 | 662 | 420 | 0 |
| 31 Dec 15 | 1,179 | 509 | 355 | 0 |
| 31 Dec 14 | 995 | 355 | 364 | 0 |
| 30 Sep 14 | 895 | 279 | 367 | 0 |
| 30 Jun 14 | 860 | 251 | 367 | 0 |
| 31 Mar 14 | 981 | 235 | 526 | 0 |
| 31 Dec 13 | 1,038 | 170 | 690 | 0 |
Quality Earnings: 000813 has high quality earnings.
Growing Profit Margin: 000813 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000813's earnings have declined by 63.7% per year over the past 5 years.
Accelerating Growth: 000813 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 000813 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-1.5%).
Return on Equity
High ROE: 000813's Return on Equity (0.6%) is considered low.